AU2019220607B2 - Modified adenoviruses - Google Patents
Modified adenoviruses Download PDFInfo
- Publication number
- AU2019220607B2 AU2019220607B2 AU2019220607A AU2019220607A AU2019220607B2 AU 2019220607 B2 AU2019220607 B2 AU 2019220607B2 AU 2019220607 A AU2019220607 A AU 2019220607A AU 2019220607 A AU2019220607 A AU 2019220607A AU 2019220607 B2 AU2019220607 B2 AU 2019220607B2
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- car
- mutation
- adenovirus
- rule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802539.5A GB201802539D0 (en) | 2018-02-16 | 2018-02-16 | Modified adenoviruses |
| GB1802539.5 | 2018-02-16 | ||
| PCT/GB2019/050380 WO2019158914A1 (en) | 2018-02-16 | 2019-02-13 | Modified adenoviruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019220607A1 AU2019220607A1 (en) | 2020-09-17 |
| AU2019220607B2 true AU2019220607B2 (en) | 2024-02-15 |
Family
ID=61783770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019220607A Active AU2019220607B2 (en) | 2018-02-16 | 2019-02-13 | Modified adenoviruses |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12318418B2 (enExample) |
| EP (1) | EP3737403B1 (enExample) |
| JP (3) | JP7862138B2 (enExample) |
| KR (1) | KR102687425B1 (enExample) |
| CN (2) | CN118834841A (enExample) |
| AU (1) | AU2019220607B2 (enExample) |
| CA (1) | CA3090859C (enExample) |
| DK (1) | DK3737403T5 (enExample) |
| ES (1) | ES2968387T3 (enExample) |
| FI (1) | FI3737403T3 (enExample) |
| GB (1) | GB201802539D0 (enExample) |
| IL (1) | IL276535B2 (enExample) |
| PL (1) | PL3737403T3 (enExample) |
| PT (1) | PT3737403T (enExample) |
| SG (1) | SG11202007470QA (enExample) |
| WO (1) | WO2019158914A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| GB201802539D0 (en) * | 2018-02-16 | 2018-04-04 | Univ College Cardiff Consultants Ltd | Modified adenoviruses |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| WO2021205364A1 (en) * | 2020-04-07 | 2021-10-14 | Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. | Engineered oncolytic adenovirus |
| CA3209730A1 (en) * | 2021-03-29 | 2022-10-06 | Alan Parker | Modified adenovirus |
| GB202214580D0 (en) | 2022-10-04 | 2022-11-16 | Univ College Cardiff Consultants Ltd | Adenoviral vector therapy |
| GB202314435D0 (en) | 2023-09-20 | 2023-11-01 | Univ College Cardiff Consultants Ltd | Modified adenovirus |
| CN121203037B (zh) * | 2025-09-26 | 2026-05-12 | 北京因诺惟康医药科技有限公司 | 基于整合素改造的特异性靶向心脏及肌肉的aav9优势突变体 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009098492A2 (en) * | 2008-02-07 | 2009-08-13 | Andrew Baker | Modulation of adenoviral tropism |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1516055A4 (en) | 2002-01-24 | 2007-08-08 | Scripps Research Inst | FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS |
| CA2519680A1 (en) * | 2003-03-28 | 2004-11-18 | The Scripps Research Institute | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| GB0520068D0 (en) * | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| ES2367227T3 (es) * | 2007-03-14 | 2011-10-31 | Institut Catala D'oncologia | Adenovirus con mutaciones en el dominio de retención en el retículo endoplasmático de la proteína e3-19k y su utilización en el tratamiento del cáncer. |
| AU2011306846B2 (en) * | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| EP3247807B1 (en) | 2015-01-20 | 2020-12-16 | Adcure Biotechnologies, LLC. | Detargeted adenovirus variants and related methods |
| GB201802539D0 (en) * | 2018-02-16 | 2018-04-04 | Univ College Cardiff Consultants Ltd | Modified adenoviruses |
-
2018
- 2018-02-16 GB GBGB1802539.5A patent/GB201802539D0/en not_active Ceased
-
2019
- 2019-02-13 JP JP2020543282A patent/JP7862138B2/ja active Active
- 2019-02-13 FI FIEP19711157.8T patent/FI3737403T3/fi active
- 2019-02-13 CN CN202410794965.6A patent/CN118834841A/zh active Pending
- 2019-02-13 KR KR1020207026679A patent/KR102687425B1/ko active Active
- 2019-02-13 PT PT197111578T patent/PT3737403T/pt unknown
- 2019-02-13 PL PL19711157.8T patent/PL3737403T3/pl unknown
- 2019-02-13 ES ES19711157T patent/ES2968387T3/es active Active
- 2019-02-13 EP EP19711157.8A patent/EP3737403B1/en active Active
- 2019-02-13 US US16/970,003 patent/US12318418B2/en active Active
- 2019-02-13 CA CA3090859A patent/CA3090859C/en active Active
- 2019-02-13 SG SG11202007470QA patent/SG11202007470QA/en unknown
- 2019-02-13 CN CN201980026226.XA patent/CN112020368B/zh active Active
- 2019-02-13 IL IL276535A patent/IL276535B2/en unknown
- 2019-02-13 WO PCT/GB2019/050380 patent/WO2019158914A1/en not_active Ceased
- 2019-02-13 AU AU2019220607A patent/AU2019220607B2/en active Active
- 2019-02-13 DK DK19711157.8T patent/DK3737403T5/da active
-
2023
- 2023-11-10 JP JP2023191972A patent/JP2024020345A/ja active Pending
-
2025
- 2025-02-19 JP JP2025025180A patent/JP2025081522A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009098492A2 (en) * | 2008-02-07 | 2009-08-13 | Andrew Baker | Modulation of adenoviral tropism |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2968387T3 (es) | 2024-05-09 |
| CA3090859C (en) | 2025-04-01 |
| IL276535B1 (en) | 2025-03-01 |
| KR102687425B1 (ko) | 2024-07-22 |
| IL276535B2 (en) | 2025-07-01 |
| JP2024020345A (ja) | 2024-02-14 |
| JP2025081522A (ja) | 2025-05-27 |
| IL276535A (en) | 2020-09-30 |
| PL3737403T3 (pl) | 2024-03-18 |
| PT3737403T (pt) | 2024-01-24 |
| WO2019158914A1 (en) | 2019-08-22 |
| DK3737403T5 (da) | 2024-08-26 |
| JP2021513843A (ja) | 2021-06-03 |
| FI3737403T3 (fi) | 2024-01-17 |
| SG11202007470QA (en) | 2020-09-29 |
| CA3090859A1 (en) | 2019-08-22 |
| EP3737403A1 (en) | 2020-11-18 |
| JP7862138B2 (ja) | 2026-05-19 |
| CN112020368A (zh) | 2020-12-01 |
| AU2019220607A1 (en) | 2020-09-17 |
| CN118834841A (zh) | 2024-10-25 |
| EP3737403B1 (en) | 2024-01-03 |
| CN112020368B (zh) | 2024-07-12 |
| US20210100855A1 (en) | 2021-04-08 |
| KR20200122346A (ko) | 2020-10-27 |
| DK3737403T3 (da) | 2024-01-22 |
| US12318418B2 (en) | 2025-06-03 |
| GB201802539D0 (en) | 2018-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3090859C (en) | MODIFIED ADENOVIRUS | |
| JP7066812B2 (ja) | 癌を治療するための治療用組成物及び使用方法 | |
| US11419926B2 (en) | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors | |
| EP2486137B1 (en) | Replication-competent ad11p based viral vectors | |
| JP5284780B2 (ja) | 癌の治療のための単純ヘルペスウイルス２型変異体の使用 | |
| CN107921117B (zh) | Hpv疫苗 | |
| JP5075839B2 (ja) | 癌の処置のための腫瘍崩壊性アデノウイルス | |
| PT2293804E (pt) | Vírus herpes simplex (hsv) com tropismo modificado, suas utilizações e processo de preparação | |
| KR102887400B1 (ko) | 암 치료요법 | |
| HK40030481A (en) | Modified adenoviruses | |
| HK40030481B (en) | Modified adenoviruses | |
| CN101744848B (zh) | Fhl3在制备用于治疗肿瘤的药物中的用途 | |
| US20240180982A1 (en) | Modified adenovirus | |
| KR20230095830A (ko) | 면역 회피성 항종양 아데노바이러스 | |
| JP2003250579A (ja) | 細胞特異的発現複製ベクター | |
| WO2024074825A1 (en) | Adenoviral vector therapy | |
| CN120437310A (zh) | 基于外泌体的5-fu靶向递送系统及其制备方法与应用 | |
| CN117025674A (zh) | 一种重组溶瘤病毒及制备方法与应用 | |
| CA2627638A1 (en) | Conditionally replicating viruses and methods for cancer virotherapy | |
| Draper et al. | 1027. A 4-Week Safety Study of Reolysin® Administered by Daily Intravenous Infusion to Cynomolgus Monkeys, with a 4-Week Recovery Period |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| GD | Licence registered |
Name of requester: TROCEPT THERAPEUTICS LIMITED |